Early and Sustained Treatment With Omalizumab Significantly Improves Quality of Life in Patients With Chronic Spontaneous Urticaria: Analysis From a Worldwide Real-World Database (AWARE Study)

Maurer M et al.

Over the 2-year study, AWARE described clinical characteristics, treatment patterns, disease activity and the impact on HRQoL.

Kaplan A et al.

At baseline, the mean (SD) age of patients was 47.0 (15.0), 74.2% were women, and 46.1% had angioedema (Table 1).

Staubach P et al.

The effectiveness and safety of omalizumab in CSU have been demonstrated in several randomized trials and confirmed in real-life studies.

We aimed to investigate the impact of early and sustained omalizumab treatment on HRQoL of patients with CSU in real-life from A World-wide Anti-IgE-Refractory chronic urticaria (OCLI) patient Evaluation (AWARE) study.

INTRODUCTION AND OBJECTIVES

Pedro A. Laires1, Nico Janssens1, Albert Kandra1, Nathalie Barbier1, Serge Smeets1, Maria-Magdalena Balp1, Karsten Weller1

MATERIALS AND METHODS

INTRODUCTION AND OBJECTIVES

The mean (SD) DLQI score at baseline and Year 1 was 9.0 (6.2) and 4.3 (5.0), respectively, in overall patients with poorly controlled disease at baseline (Figure 1).

Staubach P et al.

The effectiveness and safety of omalizumab in CSU have been demonstrated in several randomized trials and confirmed in real-life studies.

We aimed to investigate the impact of early and sustained omalizumab treatment on HRQoL of patients with CSU in real-life from A World-wide Anti-IgE-Refractory chronic urticaria (OCLI) patient Evaluation (AWARE) study.

INTRODUCTION AND OBJECTIVES

The mean (SD) DLQI score at baseline and Year 1 was 9.0 (6.2) and 4.3 (5.0), respectively, in overall patients with poorly controlled disease at baseline (Figure 1).

Staubach P et al.

The effectiveness and safety of omalizumab in CSU have been demonstrated in several randomized trials and confirmed in real-life studies.

We aimed to investigate the impact of early and sustained omalizumab treatment on HRQoL of patients with CSU in real-life from A World-wide Anti-IgE-Refractory chronic urticaria (OCLI) patient Evaluation (AWARE) study.

INTRODUCTION AND OBJECTIVES

The mean (SD) DLQI score at baseline and Year 1 was 9.0 (6.2) and 4.3 (5.0), respectively, in overall patients with poorly controlled disease at baseline (Figure 1).

Staubach P et al.

The effectiveness and safety of omalizumab in CSU have been demonstrated in several randomized trials and confirmed in real-life studies.

We aimed to investigate the impact of early and sustained omalizumab treatment on HRQoL of patients with CSU in real-life from A World-wide Anti-IgE-Refractory chronic urticaria (OCLI) patient Evaluation (AWARE) study.

INTRODUCTION AND OBJECTIVES

The mean (SD) DLQI score at baseline and Year 1 was 9.0 (6.2) and 4.3 (5.0), respectively, in overall patients with poorly controlled disease at baseline (Figure 1).

Staubach P et al.

The effectiveness and safety of omalizumab in CSU have been demonstrated in several randomized trials and confirmed in real-life studies.

We aimed to investigate the impact of early and sustained omalizumab treatment on HRQoL of patients with CSU in real-life from A World-wide Anti-IgE-Refractory chronic urticaria (OCLI) patient Evaluation (AWARE) study.